Immunoglobulins Market is anticipated to reach US$ 20,757.1

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
18
Immunoglobulins Market is anticipated to reach US$ 20,757.1 Mn by 2026 - TMR

Albany, New York, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Transparency Market Research (TMR) has published a new report titled, “ Immunoglobulins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global immunoglobulins market was valued at US$ 10,980 Mn in 2017. The market is anticipated to reach US$ 20,757.1 Mn by 2026, expanding at a CAGR of 7.2% during the forecast period. Rise in incidences of autoimmune, neurological, hematological disorders, and increasing geriatric population are expected to augment the global market from 2018 to 2026. The global immunoglobulins market is projected to expand owing to increasing healthcare investments, acceptance and rising demand for subcutaneous infusion IG, and rise in usage of off-label indications in various economies.

Request to View Sample of Report - https://www.transparencymarketresearch.com/sa...p_id=52353

Rise in prevalence of autoimmune, neurological and hematological disorders is propelling the global market

The global immunoglobulin market is expanding at a high growth rate driven by an increase in prevalence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, Kawasaki syndrome, systemic lupus erythematosus, and rheumatoid arthritis. According to the Immune Deficiency Foundation (IDF), approximately 83 people per 100,000 in the U.S. suffer from primary immunodeficiency, and there are more than 5 million undiagnosed cases in the U.S. alone. About 6 million people are suffering from Primary immunodeficiency (PID). As of June 2018, the occurrence of myasthenia gravis in the U.S. was assessed at 14 to 20 per 100,000, or around 36,000 to 60,000 cases. According to the research published by NORD (National organization for rare disorders), in the U.S., the prevalence of ITP in adults and children’s has also increased.

Request PDF Brochure of Report - https://www.transparencymarketresearch.com/sa...p_id=52353

Increase in global geriatric population is driving the need for effective treatment, globally

Prevalence of several diseases, such as cancer, diabetes, and neurological disorders, is rising due to a rapidly increasing geriatric population, resulting in surge in incidences of secondary Immunodeficiencies (SID), more common than PID. According to the WHO, the global geriatric population is expected to increase from 524 million in 2010 to 1.5 billion by 2050.

Rising geriatric population demands better treatment options for newer diseases, which in turn, would provide opportunities for companies operating in the global immunoglobulin market.

Request For Discount On This Report - https://www.transparencymarketresearch.com/sa...p_id=52353

Acceptance and rising demand for subcutaneous infusion IG and rising immunoglobulin usage in off-label indication is an advantage to the market

Awareness related to subcutaneous infusion has increased due to its easy administration as compared to intravenous injection. Acceptance of subcutaneous immunoglobulin (SCIG) infusion is rising, as it offers advantage for patients with lowers venous access and improves the quality of life of patients. In few patients with IG replacements, SCIG is more advantageous. Moreover, steady increase in the usage of immunoglobulins for the treatment of off-label indications is expected to boost the global market. Common off-label indications treated with intravenous & subcutaneous immunoglobulins are Guillain-Barre syndrome, multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis.

Request For Custom Research - https://www.transparencymarketresearch.com/sa...p_id=52353

North America dominates the global market owing to rise in demand for intravenous immunoglobulin infusion (IVIG) and adoption of subcutaneous immunoglobulin infusions (SCIG)

North America dominates the global immunoglobulin market presence of major players account for a prominent share in this region and rising prevalence of disorders with new diseases in line. IVIG is treated as the strong way to overcome autoimmune and neurological diseases, as it is a faster and effective therapy with better understanding of the antibody deficiency.

SCIG is gaining trust and popularity among children and the geriatric population, as it is easy to administer and preference of homecare settings. Therefore, easy adoption of SCIG is fuelling the market in the region.

Browse Press Release - https://www.transparencymarketresearch.com/pr...market.htm

Worldwide increase in plasma production and benefits of immunoglobulins in newer indications offer significant opportunities to new entrants

Rise in yielding plasma fulfills the global demand for plasma products, which is expected to provide lucrative opportunities to new players in the immunoglobulins market. Intravenous and subcutaneous immunoglobulins are employed in patients with primary and secondary immunodeficiency disorders, which helps combat infections. Various key players have been making significant investments in R&D programs for developing IVIG, SCIG, and IMIG applications in newer indications. Promising results in various novel clinical applications are expected to provide growth opportunities to the immunoglobulins market during the forecast period.

Investments by key players is driving the immunoglobulins market

Key players dominating the global immunoglobulins markets are Shire, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A., Octapharma, China Biologic Products Holdings, Inc, Biotest AG, Sanquin, and LFB SA. Key players are focusing on geographic expansion through acquisitions and collaborations to enhance their footprint in the global immunoglobulins market.

More Trending Reports by Transparency Market Research:

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Mr. Rohit Bhisey Transparency Market Research State Tower 90 State Street, Suite 700, Albany, NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email : sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com

Research Blog: http://theglobalhealthnews.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring EMC Filtration Market Dynamics and Growth Potential

Updated Category News Views 69

Overview of the EMC Filtration Market The EMC filtration market is an essential segment aimed at providing electromagnetic interference (EMI) protection across various industries. Currently valued at around USD 1.50 billion, the market is projected to grow significantly, reaching USD 2.35 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 5.15%,...

Continue Reading
BODEN Agency Partners with Microsoft to Engage Hispanic Audience

Updated Category News Views 91

Boosting Connections with the Hispanic Community Microsoft has announced a significant partnership with BODEN Agency, a prominent Hispanic+ communications agency, to enhance its outreach to the Hispanic community across the United States. This strategic alliance aims to make meaningful connections through targeted communication strategies that resonate with this vital...

Continue Reading
Recent Stock Sale by SoundHound AI COO Raises Investor Eyebrows

Updated Category News Views 47

Recent Actions by SoundHound AI's COO Michael Zagorsek, the Chief Operating Officer of SoundHound AI, Inc. (NASDAQ: SOUN), recently made headlines by selling a substantial amount of company stock worth over $200,000. He sold 42,001 shares at a price of $4.8795 per share, bringing the total to approximately $204,943. This sale was mainly to cover tax withholding...

Continue Reading
BioBam Unveils Enhanced OmicsBox 3.4 with CellKB Integration

Updated Category News Views 269

BioBam Introduces OmicsBox Version 3.4 BioBam, a renowned leader in the field of bioinformatics solutions, has recently rolled out the latest version of its innovative software, OmicsBox 3.4. This significant upgrade was showcased at a prominent conference dedicated to plant and animal genomics. With this release, BioBam is addressing the pressing and evolving challenges...

Continue Reading
Opportunity Knocks: Two Oversold Stocks Ready to Rebound

Updated Category News Views 275

Seizing Market Opportunities During a Downturn In today's unpredictable financial landscape, marked by trade wars, tariffs, and economic concerns, many investors face anxiety about their portfolios. The recent market downturn has touched almost every sector, leading to widespread fear and panic among investors. However, amidst this chaos, there are potential opportunities...

Continue Reading